Jennifer Patnaik
Concepts (424)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Visual Acuity | 30 | 2026 | 481 | 5.040 |
Why?
| | Cataract | 18 | 2024 | 237 | 3.850 |
Why?
| | Macular Degeneration | 16 | 2025 | 189 | 3.770 |
Why?
| | Geographic Atrophy | 12 | 2025 | 97 | 3.560 |
Why?
| | Phacoemulsification | 14 | 2025 | 120 | 2.590 |
Why?
| | Wet Macular Degeneration | 7 | 2025 | 57 | 2.140 |
Why?
| | Registries | 10 | 2025 | 2224 | 2.130 |
Why?
| | Diabetic Retinopathy | 13 | 2024 | 204 | 2.090 |
Why?
| | Lenses, Intraocular | 6 | 2022 | 49 | 1.850 |
Why?
| | Tomography, Optical Coherence | 11 | 2025 | 261 | 1.790 |
Why?
| | Fluorescein Angiography | 10 | 2026 | 182 | 1.730 |
Why?
| | Intraocular Pressure | 12 | 2026 | 326 | 1.620 |
Why?
| | Ophthalmology | 6 | 2025 | 115 | 1.450 |
Why?
| | Cataract Extraction | 10 | 2024 | 118 | 1.390 |
Why?
| | Glaucoma | 8 | 2025 | 250 | 1.160 |
Why?
| | Optometry | 2 | 2025 | 9 | 1.130 |
Why?
| | Optometrists | 2 | 2025 | 8 | 1.130 |
Why?
| | Retinopathy of Prematurity | 4 | 2026 | 178 | 1.110 |
Why?
| | Keratomileusis, Laser In Situ | 3 | 2024 | 20 | 1.100 |
Why?
| | Follow-Up Studies | 26 | 2026 | 5276 | 1.080 |
Why?
| | Retinal Detachment | 6 | 2023 | 70 | 0.970 |
Why?
| | Photorefractive Keratectomy | 2 | 2024 | 21 | 0.950 |
Why?
| | Retrospective Studies | 57 | 2026 | 16647 | 0.940 |
Why?
| | Fovea Centralis | 1 | 2025 | 24 | 0.940 |
Why?
| | Acanthamoeba Keratitis | 1 | 2025 | 4 | 0.930 |
Why?
| | Eye Infections, Parasitic | 1 | 2025 | 6 | 0.930 |
Why?
| | Myopia | 7 | 2024 | 59 | 0.920 |
Why?
| | Keratotomy, Radial | 2 | 2022 | 10 | 0.910 |
Why?
| | Aged, 80 and over | 29 | 2025 | 8009 | 0.910 |
Why?
| | Aged | 50 | 2026 | 25297 | 0.810 |
Why?
| | Burnout, Professional | 3 | 2025 | 469 | 0.810 |
Why?
| | Humans | 122 | 2026 | 142675 | 0.790 |
Why?
| | Refraction, Ocular | 6 | 2024 | 47 | 0.780 |
Why?
| | Capsule Opacification | 2 | 2021 | 22 | 0.730 |
Why?
| | Intraoperative Complications | 6 | 2024 | 154 | 0.720 |
Why?
| | Presbyopia | 1 | 2022 | 15 | 0.710 |
Why?
| | Retinal Drusen | 4 | 2024 | 31 | 0.710 |
Why?
| | Eye Diseases | 2 | 2020 | 94 | 0.710 |
Why?
| | Uveitis | 4 | 2025 | 147 | 0.700 |
Why?
| | Posterior Capsulotomy | 1 | 2021 | 7 | 0.700 |
Why?
| | Posterior Capsule of the Lens | 1 | 2021 | 11 | 0.700 |
Why?
| | Female | 76 | 2026 | 76889 | 0.700 |
Why?
| | Trabeculectomy | 5 | 2025 | 75 | 0.690 |
Why?
| | Lasers, Solid-State | 1 | 2021 | 23 | 0.690 |
Why?
| | National Eye Institute (U.S.) | 1 | 2020 | 6 | 0.670 |
Why?
| | Surveys and Questionnaires | 13 | 2025 | 5952 | 0.670 |
Why?
| | Automobile Driving | 2 | 2022 | 153 | 0.640 |
Why?
| | Colorado | 22 | 2026 | 4569 | 0.640 |
Why?
| | Male | 69 | 2026 | 71074 | 0.630 |
Why?
| | Glaucoma, Open-Angle | 4 | 2023 | 104 | 0.620 |
Why?
| | Retinal Neovascularization | 1 | 2019 | 28 | 0.620 |
Why?
| | Laser Therapy | 1 | 2021 | 132 | 0.610 |
Why?
| | Dementia | 1 | 2023 | 294 | 0.610 |
Why?
| | Vitrectomy | 6 | 2025 | 72 | 0.590 |
Why?
| | Estrogen Replacement Therapy | 1 | 2019 | 141 | 0.580 |
Why?
| | Middle Aged | 38 | 2026 | 35224 | 0.570 |
Why?
| | Lens, Crystalline | 1 | 2020 | 136 | 0.560 |
Why?
| | Postoperative Complications | 6 | 2024 | 2869 | 0.560 |
Why?
| | Lasers, Excimer | 3 | 2024 | 30 | 0.550 |
Why?
| | Metformin | 1 | 2021 | 329 | 0.530 |
Why?
| | Angiogenesis Inhibitors | 3 | 2026 | 232 | 0.530 |
Why?
| | Strabismus | 3 | 2023 | 70 | 0.520 |
Why?
| | Complement Activation | 5 | 2025 | 410 | 0.510 |
Why?
| | West Nile Fever | 3 | 2011 | 56 | 0.510 |
Why?
| | Internal Medicine | 1 | 2019 | 275 | 0.490 |
Why?
| | Emergency Medicine | 1 | 2019 | 258 | 0.490 |
Why?
| | Laser Coagulation | 3 | 2026 | 76 | 0.490 |
Why?
| | Refractive Errors | 3 | 2025 | 36 | 0.480 |
Why?
| | Complement System Proteins | 4 | 2025 | 311 | 0.470 |
Why?
| | Choroid | 3 | 2025 | 78 | 0.470 |
Why?
| | Prevalence | 7 | 2025 | 2805 | 0.460 |
Why?
| | Family Practice | 1 | 2019 | 413 | 0.460 |
Why?
| | Cross-Sectional Studies | 12 | 2025 | 5726 | 0.460 |
Why?
| | Self Report | 2 | 2022 | 861 | 0.450 |
Why?
| | Breast Neoplasms | 3 | 2011 | 2334 | 0.430 |
Why?
| | United States | 19 | 2026 | 15496 | 0.420 |
Why?
| | Vascular Endothelial Growth Factor A | 4 | 2026 | 555 | 0.420 |
Why?
| | Lens Implantation, Intraocular | 5 | 2022 | 79 | 0.410 |
Why?
| | Cornea | 3 | 2025 | 155 | 0.410 |
Why?
| | Biomarkers | 9 | 2025 | 4227 | 0.410 |
Why?
| | Multimodal Imaging | 2 | 2025 | 120 | 0.400 |
Why?
| | Corneal Transplantation | 2 | 2025 | 17 | 0.400 |
Why?
| | Internet | 4 | 2023 | 695 | 0.400 |
Why?
| | Glucocorticoids | 4 | 2026 | 539 | 0.390 |
Why?
| | Commerce | 2 | 2013 | 77 | 0.390 |
Why?
| | Vitreous Body | 4 | 2022 | 116 | 0.390 |
Why?
| | Diabetes Mellitus | 5 | 2024 | 1084 | 0.390 |
Why?
| | Fluocinolone Acetonide | 2 | 2023 | 15 | 0.380 |
Why?
| | Smoking Prevention | 1 | 2013 | 170 | 0.370 |
Why?
| | Tobacco Products | 1 | 2013 | 89 | 0.360 |
Why?
| | Risk Factors | 14 | 2025 | 10569 | 0.360 |
Why?
| | Macula Lutea | 2 | 2023 | 18 | 0.360 |
Why?
| | Ophthalmologic Surgical Procedures | 2 | 2025 | 90 | 0.360 |
Why?
| | Fundus Oculi | 3 | 2025 | 87 | 0.340 |
Why?
| | Retinal Diseases | 2 | 2023 | 94 | 0.340 |
Why?
| | Disease Notification | 2 | 2011 | 16 | 0.340 |
Why?
| | Lens Capsule, Crystalline | 2 | 2021 | 13 | 0.330 |
Why?
| | Complement Factor B | 2 | 2022 | 106 | 0.310 |
Why?
| | Artificial Intelligence | 2 | 2024 | 358 | 0.310 |
Why?
| | Treatment Outcome | 12 | 2026 | 11341 | 0.300 |
Why?
| | Comorbidity | 2 | 2011 | 1632 | 0.300 |
Why?
| | Tonometry, Ocular | 3 | 2025 | 103 | 0.300 |
Why?
| | Eye Injuries | 2 | 2021 | 53 | 0.300 |
Why?
| | Diabetes Mellitus, Type 2 | 4 | 2023 | 2587 | 0.280 |
Why?
| | Tertiary Care Centers | 2 | 2026 | 185 | 0.280 |
Why?
| | Infant | 13 | 2026 | 9849 | 0.270 |
Why?
| | Bangladesh | 3 | 2022 | 60 | 0.260 |
Why?
| | Hepatitis A | 2 | 2011 | 29 | 0.260 |
Why?
| | Healthcare Disparities | 2 | 2025 | 693 | 0.260 |
Why?
| | West Nile virus | 1 | 2007 | 40 | 0.260 |
Why?
| | Adult | 24 | 2026 | 39754 | 0.250 |
Why?
| | Gestational Age | 4 | 2026 | 970 | 0.250 |
Why?
| | Time Factors | 7 | 2025 | 7008 | 0.250 |
Why?
| | Health Promotion | 1 | 2013 | 760 | 0.250 |
Why?
| | Local Government | 1 | 2006 | 25 | 0.250 |
Why?
| | Pars Planitis | 1 | 2026 | 6 | 0.250 |
Why?
| | Restaurants | 1 | 2006 | 22 | 0.240 |
Why?
| | Prospective Studies | 7 | 2025 | 7845 | 0.240 |
Why?
| | Vision Disorders | 3 | 2022 | 175 | 0.240 |
Why?
| | Chronic Disease | 2 | 2011 | 1818 | 0.240 |
Why?
| | Keratoconjunctivitis | 1 | 2026 | 11 | 0.240 |
Why?
| | Blepharitis | 1 | 2026 | 9 | 0.240 |
Why?
| | Public Health Administration | 1 | 2006 | 72 | 0.240 |
Why?
| | Scleritis | 2 | 2025 | 28 | 0.240 |
Why?
| | Mass Screening | 2 | 2024 | 1317 | 0.230 |
Why?
| | Retinal Degeneration | 1 | 2026 | 40 | 0.230 |
Why?
| | Blindness | 1 | 2026 | 50 | 0.230 |
Why?
| | Eye Proteins | 1 | 2026 | 92 | 0.230 |
Why?
| | Visual Fields | 1 | 2026 | 117 | 0.230 |
Why?
| | Chemokine CCL5 | 2 | 2023 | 42 | 0.230 |
Why?
| | Ciliary Body | 1 | 2025 | 40 | 0.220 |
Why?
| | Pilocarpine | 1 | 2025 | 16 | 0.220 |
Why?
| | Keratoconus | 1 | 2025 | 23 | 0.220 |
Why?
| | Pemphigoid, Benign Mucous Membrane | 1 | 2024 | 6 | 0.220 |
Why?
| | Withholding Treatment | 1 | 2025 | 79 | 0.220 |
Why?
| | Occupational Stress | 1 | 2025 | 43 | 0.210 |
Why?
| | Surgery, Plastic | 1 | 2025 | 50 | 0.210 |
Why?
| | Quality of Life | 5 | 2023 | 3068 | 0.210 |
Why?
| | Education, Distance | 1 | 2025 | 60 | 0.210 |
Why?
| | Birth Weight | 3 | 2022 | 520 | 0.210 |
Why?
| | Retinoblastoma | 1 | 2024 | 50 | 0.210 |
Why?
| | Aberrometry | 2 | 2021 | 9 | 0.210 |
Why?
| | Child | 14 | 2026 | 22376 | 0.210 |
Why?
| | Young Adult | 7 | 2026 | 13817 | 0.210 |
Why?
| | Optics and Photonics | 2 | 2021 | 41 | 0.200 |
Why?
| | Disease Progression | 4 | 2025 | 2851 | 0.200 |
Why?
| | Adolescent | 12 | 2026 | 22135 | 0.200 |
Why?
| | Telemedicine | 2 | 2024 | 919 | 0.200 |
Why?
| | Macular Edema | 1 | 2023 | 48 | 0.190 |
Why?
| | Feasibility Studies | 2 | 2024 | 1047 | 0.190 |
Why?
| | Postoperative Period | 5 | 2025 | 351 | 0.190 |
Why?
| | Insulins | 1 | 2023 | 38 | 0.190 |
Why?
| | Homosexuality, Male | 2 | 2020 | 207 | 0.190 |
Why?
| | Job Satisfaction | 1 | 2025 | 232 | 0.190 |
Why?
| | Eye Burns | 1 | 2022 | 14 | 0.190 |
Why?
| | Vision, Low | 1 | 2022 | 17 | 0.190 |
Why?
| | Cohort Studies | 6 | 2022 | 5820 | 0.190 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2023 | 80 | 0.190 |
Why?
| | Endoscopy | 1 | 2025 | 326 | 0.190 |
Why?
| | Eyelid Diseases | 1 | 2022 | 23 | 0.190 |
Why?
| | Compartment Syndromes | 1 | 2022 | 36 | 0.180 |
Why?
| | Odds Ratio | 4 | 2019 | 1052 | 0.180 |
Why?
| | Incidence | 5 | 2022 | 2828 | 0.180 |
Why?
| | Eyeglasses | 1 | 2022 | 24 | 0.180 |
Why?
| | Corneal Ulcer | 1 | 2022 | 20 | 0.180 |
Why?
| | Retinal Perforations | 1 | 2022 | 18 | 0.180 |
Why?
| | Clothing | 1 | 2022 | 22 | 0.180 |
Why?
| | Infant, Newborn | 6 | 2026 | 6315 | 0.180 |
Why?
| | Patient Satisfaction | 2 | 2024 | 692 | 0.170 |
Why?
| | Ocular Hypertension | 1 | 2022 | 70 | 0.170 |
Why?
| | Weapons | 1 | 2021 | 9 | 0.170 |
Why?
| | Civil Disorders | 1 | 2021 | 8 | 0.170 |
Why?
| | Political Activism | 1 | 2021 | 9 | 0.170 |
Why?
| | Refractive Surgical Procedures | 1 | 2021 | 7 | 0.170 |
Why?
| | Neonatal Screening | 1 | 2022 | 174 | 0.170 |
Why?
| | Eye Banks | 1 | 2020 | 7 | 0.170 |
Why?
| | Child, Preschool | 10 | 2026 | 11599 | 0.170 |
Why?
| | Sickness Impact Profile | 1 | 2020 | 58 | 0.170 |
Why?
| | Glaucoma Drainage Implants | 1 | 2021 | 46 | 0.160 |
Why?
| | Posterior Capsular Rupture, Ocular | 1 | 2020 | 6 | 0.160 |
Why?
| | Perception | 2 | 2021 | 370 | 0.160 |
Why?
| | Glycation End Products, Advanced | 1 | 2021 | 86 | 0.160 |
Why?
| | Health Services Accessibility | 2 | 2026 | 1066 | 0.160 |
Why?
| | Accidents, Traffic | 1 | 2022 | 190 | 0.160 |
Why?
| | SEER Program | 2 | 2011 | 220 | 0.160 |
Why?
| | Neurodegenerative Diseases | 1 | 2022 | 140 | 0.160 |
Why?
| | Scleral Buckling | 1 | 2019 | 15 | 0.160 |
Why?
| | Retinal Hemorrhage | 1 | 2019 | 21 | 0.160 |
Why?
| | Vitreoretinopathy, Proliferative | 1 | 2019 | 13 | 0.150 |
Why?
| | Hepatitis C | 1 | 2022 | 249 | 0.150 |
Why?
| | Language | 1 | 2023 | 320 | 0.150 |
Why?
| | Legislation, Drug | 1 | 2020 | 77 | 0.150 |
Why?
| | Protective Factors | 1 | 2019 | 102 | 0.150 |
Why?
| | Health Status Disparities | 1 | 2023 | 313 | 0.150 |
Why?
| | Head Injuries, Closed | 1 | 2019 | 49 | 0.150 |
Why?
| | Oculomotor Muscles | 1 | 2020 | 85 | 0.150 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2019 | 74 | 0.150 |
Why?
| | Risk Assessment | 3 | 2019 | 3533 | 0.150 |
Why?
| | Complement Membrane Attack Complex | 1 | 2019 | 38 | 0.150 |
Why?
| | Specialization | 1 | 2020 | 134 | 0.150 |
Why?
| | Complement C3a | 1 | 2019 | 41 | 0.150 |
Why?
| | Cardiovascular Diseases | 1 | 2011 | 2095 | 0.150 |
Why?
| | Uveitis, Posterior | 1 | 2019 | 12 | 0.150 |
Why?
| | Accreditation | 1 | 2019 | 97 | 0.150 |
Why?
| | Refugees | 1 | 2020 | 82 | 0.140 |
Why?
| | Choroidal Neovascularization | 1 | 2019 | 56 | 0.140 |
Why?
| | Medical Marijuana | 1 | 2020 | 122 | 0.140 |
Why?
| | Patient Care | 1 | 2019 | 119 | 0.140 |
Why?
| | Case-Control Studies | 3 | 2022 | 3601 | 0.140 |
Why?
| | Down Syndrome | 1 | 2025 | 523 | 0.140 |
Why?
| | Glaucoma, Angle-Closure | 1 | 2018 | 22 | 0.140 |
Why?
| | Curriculum | 1 | 2025 | 1032 | 0.140 |
Why?
| | Infant, Premature | 1 | 2022 | 606 | 0.140 |
Why?
| | Health Services Needs and Demand | 1 | 2020 | 277 | 0.140 |
Why?
| | Trabecular Meshwork | 1 | 2018 | 80 | 0.130 |
Why?
| | Sexually Transmitted Diseases | 3 | 2004 | 166 | 0.130 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2019 | 227 | 0.130 |
Why?
| | Marijuana Smoking | 1 | 2020 | 255 | 0.120 |
Why?
| | Marijuana Use | 1 | 2020 | 214 | 0.120 |
Why?
| | Clinical Competence | 2 | 2025 | 1218 | 0.120 |
Why?
| | Logistic Models | 2 | 2019 | 2088 | 0.120 |
Why?
| | Recovery of Function | 1 | 2019 | 691 | 0.110 |
Why?
| | Disease Management | 1 | 2019 | 636 | 0.110 |
Why?
| | Population Surveillance | 2 | 2011 | 490 | 0.110 |
Why?
| | Aging | 1 | 2026 | 1963 | 0.110 |
Why?
| | Inflammation | 3 | 2023 | 2883 | 0.110 |
Why?
| | Proportional Hazards Models | 2 | 2024 | 1286 | 0.110 |
Why?
| | Education, Medical, Graduate | 1 | 2019 | 543 | 0.110 |
Why?
| | Disease Outbreaks | 2 | 2008 | 423 | 0.100 |
Why?
| | Retinal Pigment Epithelium | 2 | 2024 | 78 | 0.100 |
Why?
| | Condoms | 2 | 2004 | 98 | 0.100 |
Why?
| | Physicians | 1 | 2022 | 925 | 0.100 |
Why?
| | Intravitreal Injections | 2 | 2026 | 70 | 0.100 |
Why?
| | Research Design | 1 | 2019 | 1113 | 0.090 |
Why?
| | Sexual Behavior | 4 | 2004 | 485 | 0.090 |
Why?
| | Melanoma | 1 | 2019 | 797 | 0.090 |
Why?
| | Medicare | 2 | 2024 | 813 | 0.090 |
Why?
| | Skin Neoplasms | 1 | 2019 | 854 | 0.090 |
Why?
| | Axial Length, Eye | 2 | 2024 | 16 | 0.090 |
Why?
| | Hypoglycemic Agents | 1 | 2021 | 1388 | 0.090 |
Why?
| | Immunologic Factors | 2 | 2024 | 255 | 0.080 |
Why?
| | Diagnostic Errors | 1 | 2011 | 175 | 0.080 |
Why?
| | Primary Prevention | 1 | 2011 | 195 | 0.080 |
Why?
| | Shellfish Poisoning | 1 | 2009 | 1 | 0.080 |
Why?
| | Vibrio Infections | 1 | 2009 | 2 | 0.080 |
Why?
| | Shellfish | 1 | 2009 | 6 | 0.080 |
Why?
| | Food Industry | 1 | 2009 | 8 | 0.080 |
Why?
| | Food Microbiology | 1 | 2009 | 73 | 0.070 |
Why?
| | Sex Factors | 2 | 2025 | 2066 | 0.070 |
Why?
| | Cause of Death | 1 | 2011 | 457 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 1 | 2011 | 917 | 0.070 |
Why?
| | Internship and Residency | 1 | 2019 | 1233 | 0.070 |
Why?
| | Mortality | 1 | 2011 | 360 | 0.070 |
Why?
| | Academic Medical Centers | 2 | 2022 | 534 | 0.070 |
Why?
| | Cryptosporidiosis | 1 | 2008 | 22 | 0.070 |
Why?
| | Antineoplastic Agents | 1 | 2019 | 2171 | 0.070 |
Why?
| | Anti-Inflammatory Agents | 2 | 2022 | 477 | 0.070 |
Why?
| | Disease Reservoirs | 1 | 2007 | 25 | 0.070 |
Why?
| | Maternal-Child Health Centers | 1 | 2007 | 8 | 0.070 |
Why?
| | Culicidae | 1 | 2007 | 33 | 0.070 |
Why?
| | Sentinel Surveillance | 1 | 2007 | 46 | 0.070 |
Why?
| | Gastroenteritis | 1 | 2008 | 62 | 0.070 |
Why?
| | Health Services Administration | 1 | 2007 | 8 | 0.070 |
Why?
| | Relief Work | 1 | 2007 | 18 | 0.070 |
Why?
| | Chickens | 1 | 2007 | 191 | 0.060 |
Why?
| | Telephone | 1 | 2008 | 171 | 0.060 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2019 | 850 | 0.060 |
Why?
| | Birds | 1 | 2007 | 91 | 0.060 |
Why?
| | Geography | 1 | 2007 | 201 | 0.060 |
Why?
| | Horses | 1 | 2007 | 204 | 0.060 |
Why?
| | Health Care Surveys | 1 | 2008 | 533 | 0.060 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2023 | 3833 | 0.060 |
Why?
| | Visual Field Tests | 1 | 2026 | 34 | 0.060 |
Why?
| | Disasters | 1 | 2007 | 99 | 0.060 |
Why?
| | Smoking | 1 | 2013 | 1552 | 0.060 |
Why?
| | Environment | 1 | 2007 | 306 | 0.060 |
Why?
| | Immunoglobulins | 1 | 2006 | 162 | 0.060 |
Why?
| | Immunization Programs | 1 | 2007 | 190 | 0.060 |
Why?
| | Predictive Value of Tests | 1 | 2011 | 2083 | 0.060 |
Why?
| | Bevacizumab | 1 | 2026 | 141 | 0.060 |
Why?
| | Databases, Factual | 1 | 2011 | 1452 | 0.060 |
Why?
| | Corneal Topography | 1 | 2025 | 25 | 0.060 |
Why?
| | Miotics | 1 | 2025 | 6 | 0.060 |
Why?
| | Muscarinic Agonists | 1 | 2025 | 14 | 0.060 |
Why?
| | Azathioprine | 1 | 2025 | 48 | 0.060 |
Why?
| | Adalimumab | 1 | 2025 | 54 | 0.060 |
Why?
| | Ganglionic Stimulants | 1 | 2005 | 15 | 0.060 |
Why?
| | Tomography | 1 | 2025 | 45 | 0.060 |
Why?
| | Lubricant Eye Drops | 1 | 2024 | 9 | 0.060 |
Why?
| | Ontario | 1 | 2024 | 94 | 0.050 |
Why?
| | Infliximab | 1 | 2025 | 108 | 0.050 |
Why?
| | Mycophenolic Acid | 1 | 2025 | 120 | 0.050 |
Why?
| | Conjunctivitis | 1 | 2024 | 30 | 0.050 |
Why?
| | Retinal Neoplasms | 1 | 2024 | 42 | 0.050 |
Why?
| | Needs Assessment | 1 | 2007 | 389 | 0.050 |
Why?
| | Rwanda | 1 | 2024 | 33 | 0.050 |
Why?
| | Capacity Building | 1 | 2024 | 59 | 0.050 |
Why?
| | Ophthalmic Solutions | 1 | 2024 | 79 | 0.050 |
Why?
| | Patient Discharge | 1 | 2011 | 937 | 0.050 |
Why?
| | Attitude to Health | 1 | 2007 | 435 | 0.050 |
Why?
| | Methotrexate | 1 | 2025 | 238 | 0.050 |
Why?
| | Vision Tests | 1 | 2023 | 22 | 0.050 |
Why?
| | Hospitals, County | 1 | 2023 | 10 | 0.050 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2011 | 1065 | 0.050 |
Why?
| | Observational Studies as Topic | 1 | 2023 | 126 | 0.050 |
Why?
| | Health Surveys | 2 | 2021 | 506 | 0.050 |
Why?
| | Postoperative Care | 1 | 2025 | 276 | 0.050 |
Why?
| | Tobacco Use Disorder | 1 | 2005 | 223 | 0.050 |
Why?
| | Interleukin-4 | 1 | 2023 | 212 | 0.050 |
Why?
| | Complement Factor I | 1 | 2022 | 12 | 0.050 |
Why?
| | Electronic Health Records | 1 | 2011 | 1165 | 0.050 |
Why?
| | Mentors | 1 | 2024 | 211 | 0.050 |
Why?
| | Gonorrhea | 1 | 2003 | 65 | 0.050 |
Why?
| | Global Health | 1 | 2025 | 388 | 0.050 |
Why?
| | Aqueous Humor | 1 | 2022 | 38 | 0.050 |
Why?
| | Orbit | 1 | 2022 | 66 | 0.050 |
Why?
| | Hospitals, Pediatric | 1 | 2026 | 545 | 0.050 |
Why?
| | Phenotype | 2 | 2022 | 3160 | 0.050 |
Why?
| | Alanine Transaminase | 1 | 2022 | 147 | 0.050 |
Why?
| | Drug Implants | 1 | 2022 | 83 | 0.050 |
Why?
| | Cluster Analysis | 1 | 2023 | 527 | 0.050 |
Why?
| | Nicotine | 1 | 2005 | 331 | 0.040 |
Why?
| | Communication Barriers | 1 | 2023 | 123 | 0.040 |
Why?
| | Reference Standards | 1 | 2022 | 181 | 0.040 |
Why?
| | Capsulorhexis | 1 | 2021 | 8 | 0.040 |
Why?
| | Albumins | 1 | 2022 | 114 | 0.040 |
Why?
| | Safety-net Providers | 1 | 2023 | 124 | 0.040 |
Why?
| | Morbidity | 1 | 2022 | 319 | 0.040 |
Why?
| | Fibrinogen | 1 | 2022 | 179 | 0.040 |
Why?
| | Dissent and Disputes | 1 | 2021 | 18 | 0.040 |
Why?
| | Retinal Ganglion Cells | 1 | 2022 | 121 | 0.040 |
Why?
| | Hepacivirus | 1 | 2022 | 232 | 0.040 |
Why?
| | Intraoperative Period | 1 | 2020 | 68 | 0.040 |
Why?
| | Smoking Cessation | 1 | 2005 | 434 | 0.040 |
Why?
| | Crowding | 1 | 2021 | 37 | 0.040 |
Why?
| | Biometry | 1 | 2021 | 68 | 0.040 |
Why?
| | Myotomy | 1 | 2020 | 14 | 0.040 |
Why?
| | Myanmar | 1 | 2020 | 6 | 0.040 |
Why?
| | Risk-Taking | 1 | 2003 | 332 | 0.040 |
Why?
| | Rupture | 1 | 2020 | 86 | 0.040 |
Why?
| | Immunosuppressive Agents | 1 | 2025 | 842 | 0.040 |
Why?
| | Vision, Binocular | 1 | 2020 | 47 | 0.040 |
Why?
| | Adrenal Cortex Hormones | 1 | 2023 | 498 | 0.040 |
Why?
| | Eye Movements | 1 | 2020 | 92 | 0.040 |
Why?
| | Survival Rate | 1 | 2024 | 2003 | 0.040 |
Why?
| | HIV | 1 | 2020 | 247 | 0.040 |
Why?
| | Health Education | 1 | 2003 | 355 | 0.040 |
Why?
| | Chromatography, Liquid | 1 | 2021 | 450 | 0.040 |
Why?
| | Canada | 1 | 2020 | 422 | 0.040 |
Why?
| | C-Reactive Protein | 1 | 2021 | 417 | 0.040 |
Why?
| | Remission, Spontaneous | 1 | 2019 | 39 | 0.040 |
Why?
| | Pilot Projects | 1 | 2024 | 1830 | 0.040 |
Why?
| | Microscopy, Acoustic | 1 | 2018 | 9 | 0.040 |
Why?
| | Attitude | 1 | 2021 | 254 | 0.040 |
Why?
| | Ophthalmoscopy | 1 | 2018 | 38 | 0.040 |
Why?
| | Pyrimidinones | 1 | 2019 | 127 | 0.040 |
Why?
| | Preoperative Period | 1 | 2019 | 144 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2023 | 1037 | 0.040 |
Why?
| | Exfoliation Syndrome | 1 | 2018 | 10 | 0.030 |
Why?
| | Corneal Pachymetry | 1 | 2018 | 16 | 0.030 |
Why?
| | Ambulatory Care | 1 | 2023 | 588 | 0.030 |
Why?
| | Pseudophakia | 1 | 2018 | 22 | 0.030 |
Why?
| | Circadian Rhythm | 1 | 2023 | 516 | 0.030 |
Why?
| | Tandem Mass Spectrometry | 1 | 2021 | 567 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2019 | 727 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2026 | 2905 | 0.030 |
Why?
| | Physical Examination | 1 | 2019 | 234 | 0.030 |
Why?
| | Prosthesis Design | 1 | 2020 | 349 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2020 | 614 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2025 | 2930 | 0.030 |
Why?
| | Ambulatory Care Facilities | 3 | 2004 | 257 | 0.030 |
Why?
| | Stents | 1 | 2021 | 542 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2024 | 936 | 0.030 |
Why?
| | Equipment Design | 1 | 2018 | 530 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2022 | 823 | 0.030 |
Why?
| | Sex Characteristics | 1 | 2022 | 782 | 0.030 |
Why?
| | Mental Health | 1 | 2022 | 767 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2023 | 3362 | 0.030 |
Why?
| | Sleep | 1 | 2023 | 903 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2019 | 1493 | 0.030 |
Why?
| | Program Evaluation | 2 | 2011 | 938 | 0.030 |
Why?
| | Anxiety | 1 | 2022 | 1088 | 0.030 |
Why?
| | Proteins | 1 | 2020 | 1016 | 0.030 |
Why?
| | Anti-Bacterial Agents | 1 | 2024 | 1892 | 0.030 |
Why?
| | Child Abuse | 1 | 2019 | 548 | 0.030 |
Why?
| | Proteomics | 1 | 2020 | 1167 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2022 | 2034 | 0.020 |
Why?
| | Protein Kinase Inhibitors | 1 | 2019 | 976 | 0.020 |
Why?
| | Depression | 1 | 2022 | 1501 | 0.020 |
Why?
| | Pandemics | 1 | 2021 | 1660 | 0.020 |
Why?
| | Animals | 3 | 2009 | 37904 | 0.020 |
Why?
| | Legionellosis | 1 | 2011 | 2 | 0.020 |
Why?
| | Blood Glucose | 1 | 2021 | 2321 | 0.020 |
Why?
| | Prognosis | 1 | 2019 | 4159 | 0.020 |
Why?
| | Medical Audit | 1 | 2011 | 73 | 0.020 |
Why?
| | Whooping Cough | 1 | 2011 | 55 | 0.020 |
Why?
| | Haemophilus Infections | 1 | 2011 | 40 | 0.020 |
Why?
| | Hospitals, Urban | 1 | 2011 | 137 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1833 | 0.020 |
Why?
| | International Classification of Diseases | 1 | 2011 | 140 | 0.020 |
Why?
| | Cryptosporidium | 1 | 2008 | 14 | 0.020 |
Why?
| | Caliciviridae Infections | 1 | 2008 | 18 | 0.020 |
Why?
| | Norovirus | 1 | 2008 | 22 | 0.020 |
Why?
| | Aid to Families with Dependent Children | 1 | 2007 | 3 | 0.020 |
Why?
| | Residence Characteristics | 1 | 2011 | 376 | 0.020 |
Why?
| | Faculty | 1 | 2008 | 147 | 0.020 |
Why?
| | Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2007 | 91 | 0.020 |
Why?
| | Medically Uninsured | 1 | 2007 | 129 | 0.020 |
Why?
| | Family Characteristics | 1 | 2008 | 196 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2011 | 1976 | 0.010 |
Why?
| | Pharmaceutical Preparations | 1 | 2007 | 170 | 0.010 |
Why?
| | Guideline Adherence | 1 | 2009 | 561 | 0.010 |
Why?
| | Maryland | 1 | 2005 | 62 | 0.010 |
Why?
| | Administration, Topical | 1 | 2005 | 152 | 0.010 |
Why?
| | Urban Health Services | 1 | 2004 | 68 | 0.010 |
Why?
| | Acute Disease | 1 | 2007 | 994 | 0.010 |
Why?
| | Office Visits | 1 | 2003 | 91 | 0.010 |
Why?
| | Syphilis | 1 | 2003 | 33 | 0.010 |
Why?
| | Administration, Oral | 1 | 2005 | 834 | 0.010 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2003 | 277 | 0.010 |
Why?
| | Risk | 1 | 2004 | 897 | 0.010 |
Why?
| | Mothers | 1 | 2007 | 768 | 0.010 |
Why?
| | Urban Population | 1 | 2004 | 481 | 0.010 |
Why?
| | HIV Infections | 1 | 2003 | 3031 | 0.000 |
Why?
|
|
Patnaik's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|